Bupropion as a modulator of drug activity
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Claims14
A method of treating treatment resistant depression, comprising administering a drug combination twice a day to a human being in need thereof for at least 8 consecutive days, wherein the drug combination comprises:
- about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form;
- and
- about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form;
- wherein the bupropion and the dextromethorphan are present in a dosage form, wherein the bupropion and the dextromethorphan are the only therapeutically active compounds in the dosage form;
- wherein the dosage form is formulated for immediate release of dextromethorphan and sustained release of bupropion;
- and
- wherein the method is more effective in treating treatment resistant depression than administering 150 mg of bupropion hydrochloride alone twice a day for at least 8 consecutive days.
A method of treating treatment resistant depression, comprising administering a drug combination once a day to a human being in need thereof for at least 8 consecutive days, wherein the drug combination comprises:
- about 210 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form;
- and
- about 90 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form;
- wherein the bupropion and the dextromethorphan are present in a dosage form, wherein the bupropion and the dextromethorphan are the only therapeutically active compounds in the dosage form;
- wherein the dosage form is formulated for immediate release of dextromethorphan and sustained release of bupropion;
- and
- wherein the method is more effective in treating treatment resistant depression than administering 210 mg of bupropion hydrochloride alone once a day for at least 8 consecutive days.
A method of treating treatment resistant depression, comprising administering one of the following drug combinations to a human being in need thereof for at least 8 consecutive days:
- about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide twice a day;
- about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide once a day;
- or
- an amount of a bupropion in the free base form or a salt form and an amount of dextromethorphan in the free form base or a salt form that provides, to the human being, about the same AUC0-24 of bupropion and about the same AUC0-24 of dextromethorphan as administering:
- about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide twice a day;
- wherein the bupropion and the dextromethorphan are present in a dosage form, wherein the bupropion and the dextromethorphan are the only therapeutically active compounds in the dosage form;
- wherein the dosage form is formulated for immediate release of dextromethorphan and sustained release of bupropion;
- and
- wherein the method is more effective in treating treatment resistant depression than administering 105 mg of bupropion hydrochloride alone twice a day for at least 8 consecutive days.
Dependencies are inferred from the claim text.